When AXL-CAR is incorporated into human primary T cells, it enables targeted tumor cell destruction, while the AXL synNotch receptor can generate IL-10 in an antigen-specific manner.153 Similarly, AXL-CAR-T cells have shown antigen-specific cytotoxicity and cytokine release capacity against triple-negative breast cancer (TNBC).154 This therapy is precisely tailored to target AXL-positive osteomyeloid leukemic and TNBC cells,153,154 and is currently under clinical investigation for refractory stage IV renal cell carcinoma (RCC) (NCT03393936) and AXL-positive sarcoma (NCT05128786). This evidence concerns the gene AXL and sarcoma.